News AI specialists Enveda and Basecamp rake in the cash AI-powered drug discovery companies Enveda and Basecamp have completed impressive funding rounds, worth $311m and $140m, respectively.
News Roche, Viking, and Syntis showcase obesity drug candidates A flurry of clinical readouts for new weight-loss therapies has seen Roche, Viking, and Syntis all showing off new drug candidates.
News Roche's IgAN hopeful sefaxersen passes phase 3 test Roche has staked a claim to the increasingly crowded IgA nephropathy (IgAN) category with phase 3 data for Ionis-partnered sefaxersen.
News Amgen's Horizon buyout delivers Sjögren's disease win Amgen's anti-CD40L drug dazodalibep has shown efficacy in Sjögren's in a phase 3 trial, raising hopes for a disease-modifying drug for the disorder.
News Pharma leaders urge Europe to halt 'slow agony' of decline Europe's top pharma firms have called on governments to take action to change the region's story from one of decay to one of "renewal and resilience."
News UK issues £45m funding call for research partnerships The NIHR has revealed the first £45m in funding for projects that can bridge the translation gap in healthcare, focusing initially on community care.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.